National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$59.95
add to cart

Rights & Permissions

topleft topright

Dietary Supplements: A Framework for Evaluating Safety (2005)
Institute of Medicine (IOM)

Citation Manager

. "3 The Framework." Dietary Supplements: A Framework for Evaluating Safety. Washington, DC: The National Academies Press, 2005.

Please select a format:

BibTeX EndNote RefMan


Page
106
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Dietary Supplements: A Framework for Evaluating Safety

TABLE 3-6 Relative Spectrum of Concern: Guidelines for Types of Evidence from Animal Studiesa

Increasing Concern

At least one acceptable, quality study showing effects of Category A at Dose > 1,000× Human Intake

At least one acceptable, quality study showing effects of Category A at Dose > 100 to < 1,000× Human Intake

At least one acceptable, quality study showing effects of Category A at Dose < 100× Human Intake

OR

OR

OR

At least one acceptable, quality study showing effects of Category B at Dose > 100× Human Intake

At least one acceptable, quality study showing effects of Category B at Dose > 10 to < 100× Human Intake

At least one acceptable, quality study showing effects of Category B at Dose < 10× Human Intake

OR

OR

OR

At least one acceptable, quality study showing effects of Category C at Dose > 10× Human Intake

OR

Studies showing adverse effects, but which cannot be interpreted because of deficiencies in design, conduct, or reporting

OR

Acceptable, quality non-oral studies indicating adverse effect from Category A, B, or C

At least one acceptable, quality study showing effects of Category C at Dose > 1 to < 10× Human Intake

At least one acceptable, quality study showing effects of Category C at Dose ≤ 1× Human Intake

a Categories A, B, and C refer to relative seriousness of a variety of adverse effects identified in animal studies, ranging from reproductive failure (A) to reduced food consumption (C). See Box 3-4 for further examples.

Information About Related Substances

Information about substances related to the dietary supplement ingredient of interest may be useful when predicting risk to human health. Such substances may be related to dietary supplement ingredients in one of several ways, such as:

  • Chemical relatedness—the ingredient or constituent of an ingredient is similar to known toxic chemicals, or is known to contain chemicals similar in structure to known toxicophores;8

8  

Chemical structures associated with potential adverse effects.

Page
106
Front Matter (R1-R20)
Executive Summary (1-18)
1 Introduction and Background (19-42)
2 Approaches Used by Others and Existing Safety Frameworks (43-84)
3 The Framework (85-125)
4 Categories of Scientific Evidence--Human Information and Data (126-155)
5 Categories of Scientific Evidence--Animal Data (156-174)
6 Categories of Scientific Evidence--Information About Related Substances (175-216)
7 Categories of Scientific Evidence--In Vitro Data (217-234)
8 Interactions (235-246)
9 Vulnerable Groups and Prevalance of Use (247-252)
10 Scientific Principles for Integrating and Evaluating the Available Data (253-268)
11 Applying the Framework: Case Studies Using the Prototype Safety Monographs (269-291)
12 Factors Influencing Use of the Safety Framework (292-296)
13 Findings and Recommendations (297-306)
Appendix A: Existing Frameworks or Systems for Evaluating the Safety of Other Substances (307-315)
Appendix B: Scope of Work and Comments to Initial July 2002 Framework (316-321)
Appendix C: Plant Family Information (322-355)
Appendix D: Chaparral: Prototype Monograph Summary (356-362)
Appendix E: Glucosamine: Prototype Monograph Summary (363-366)
Appendix F: Melatonin: Prototype Monograph Summary (367-371)
Appendix G: Chromium Picolinate: Prototype Monograph Summary (372-375)
Appendix H: Saw Palmetto: Prototype Monograph Summary (376-379)
Appendix I: Shark Cartilage: Prototype Monograph Summary (380-384)
Appendix J: Prototype Focused Monograph: Review of Liver-Related Risks for Chaparral (385-449)
Appendix K: Protoype Focused Monograph: Review of Anti-Androgenic Risks of Saw Palmetto Ingestion by Women (450-477)
Appendix L: Acknowledgements (478-480)
Appendix M: Biographical Sketches of Commitee Members (481-488)
Index (489-506)